Pproject Risk Register - PDF by ftx70437

VIEWS: 27 PAGES: 7

More Info
									                                                               Center for Genetic Engineering and Biotechnology, 
                                                               Center for Genetic Engineering and Biotechnology,
                                                              Center for Genetic Engineering and 
                                                              Biotechnology (CIGB)


 In the framework of annual meetings Biotechnology Havana the 2010 edition will focus on
 In the framework of annual meetings Biotechnology Havana, the 2010 edition will focus on 
                                          the 
 INTEGRAL CARE OF DIABETIC FOOT ULCER PATIENT USING HEBERPROT‐P
                         CIGB, Havana, CUBA.     October 20‐22nd 2010, 
                                       Symposia
1. Epidermal Growth Factor (EGF), its molecular biology, toxicology,
   pharmacogenomic.             assays.           Dr.
   pharmacogenomic Pre clinical assays (Chairman: Dr Jorge Berlanga)

2.     Integral Care to Diabetic Foot Ulcers. Current State. (Chairman: Dr. Jose
     Fernandez Montequin)

                                http://bh2010.cigb.edu.cu 
                                     bh2010@cigb.edu.cu 
By visiting http://bh2010.cigb.edu.cu you can get details about how to  register

The registration fee includes: Name badge, attendance to the Congress scientific activities, hardcopy program 
     and CD with program, abstracts and papers, attendance certificate, other auxiliary and informative 
     materials, Welcoming cocktail, and lunch during the session days (October 20‐22nd).
                                       E l R i t ti
                                       Early Registration                L t F      d O it
                                                                         Late Fee and On‐site
                                       (until June 30th, 2010)


                                       400 euros                         500 euros
                                                                         500 euros
      Private sector

      Academic                         350 euros
                                       350 euros                         400 euros
                                                                         400 euros




Registration request received after June 30th, 2010 will be processed as Late fee registration.
    18‐19th OCTOBER. CALL FOR THE BH2010 PRE‐CONGRESS COURSE‐WORKSHOP
    PRACTICAL APPLICATION OF HEBERPROT‐P IN DIABETIC FOOT ULCER PATIENTS
•     Considering the request of different specialists in DFU treatment with Heberprot‐P, is our
      interest to take advantage the Biotechnology Havana 2010 Congress celebration to previously
                                                     Pre‐Congress Course‐Workshop           Practical
      launch the invitation to participate in the Pre Congress Course Workshop entitle: “Practical
      Application of Heberprot‐P in diabetic foot ulcer patients”, which will offer the opportunity,
      mainly to international specialists to receive practical and theoretical classes in technical
      procedures to apply Heberprot‐P in diabetic wounds.
•     The              ill be held during 18‐19th f October, t the Research C t f M di l
      Th course will b h ld d i 18 19th of O t b at th R                      h Center for Medical
      Surgery (CIMEQ) in Havana City, Cuba. The participation in the pre‐congress Workshop
      Course will be optional for delegates and will admit up to 100 applicants, who will be
      selected in arrival order by registering through the Congress Website. Among the teachers
      there will b a selection of C b
      th        ill be       l ti      f Cuban d t
                                                 doctors with th b t record i t ti
                                                           ith the best     d in treating DFU with ith
      Heberprot‐P.
•     Taking into account the proximity in time between the Course – Workshop and BH2010
      congress, those delegates showing interest from now in participating in both activities will be
      granted with an attractive congress fee discount if applying before June 30th, to both
      activities as a full registration package.
       CIMEQ 18-19 OCTOBER   BH2010 PRE-CONGRESS COURSE-WORKSHOP
    PRACTICAL APPLICATION OF HEBERPROT-P IN DIABETIC FOOT ULCER PATIENTS

                                    Monday 18th October 2010
   Time                               Lecture                                        Objectives
 9:00‐9:50    The Diabetic foot as Diabetes complication.                 To describe Neuropathic and Ischemic
                                                                          Diabetic foot. Risk scale. Amputation
                                                                          criteria.

10:00‐10:50   Practical application of Heberprot‐P. First requirement :   To determine through endocrine‐
                 i     h        i i
              Patient characterization.                                   metabolic analysis and other clinical
                                                                               b li      l i      d h       li i l
                                                                          tests if the patient either qualifies or
                                                                          not for Heberprot‐P applications.

11:00‐11:50   Practical application of Heberprot‐P.            Second     To explain surgery and podiatry
                                   preparation.
              requirement: Patient preparation                            practical procedures conducted in
                                                                          patients as previous requirement to
                                                                          receive Heberprot‐P applications.


12:00‐12:50   Lunch
13:00‐13:50   Practical application of Heberprot‐P. Third requirement:    To explain practical procedures to
              Heberprot‐P infiltration.                                   infiltrate Heberprot‐P in DFU from
                                                                          Neuropathic and Ischemic patients. To
                                                                          explain how to conduct actions to
                                                                          reduce adverse reactions.

14:00‐14:50   Practical application of Heberprot‐P. Fourth                To explain how to fill it up all
              requirement.     Product     pharmaco‐surveillance.         documents for patient follow up.
              Documents to be fulfilled for patient tracking and
              follow up.
15:00‐16:50   Interactive session between teachers and applicants.        To answer all type of questions based
                                                                          in concrete previous experience
                                                                          accumulated by teachers.
                         CIMEQ 18-19 OCTOBER   BH2010 PRE-CONGRESS COURSE-WORKSHOP
                      PRACTICAL APPLICATION OF HEBERPROT-P IN DIABETIC FOOT ULCER PATIENTS


Tuesday 19th October 2010
            Time                               Practical Class                                           Objectives
          9:00‐9:50         Patient No. 1. Neuropathic     ulcer. First Heberprot‐P         To appreciate how a Neuropathic ulcer is
                            application.                                                    prepared for receiving for first time
                                                                                            Heberprot‐P infiltration, to determine ulcer
                                                                                            size by planimetric calculation, to conduct
                                                                                            Heberprot‐P infiltration.

        10:00‐10:50         Patient No. 2. Neuropathic Ulcer. Middle of wound healing.      To appreciate how an Neuropathic ulcer
                            Tissue in granulation.                                          which is progressing well in term of
                                                                                            granulation is prepared for receiving
                                                                                            Heberprot‐P infiltration.
        11:00‐11:50         Patient No. 3. Neuropathic Ulcer. Ulcer near to full healing.   To appreciate how an Neuropathic ulcer
                                                                                              hi h is        i     ll in term of
                                                                                            which i progressing well i t         f
                                                                                            granulation and is almost healed is
                                                                                            prepared for receiving Heberprot‐P
                                                                                            infiltration.
        12:00‐12:50         Lunch.
        13:00‐13:50         Patient No. 4. Ischemic ulcer. First Heberprot‐P application.   To appreciate how an Ischemic ulcer is
                                                                                            prepared for receiving for first time
                                                                                            Heberprot‐P infiltration, to determine ulcer
                                                                                            size by planimetric calculation, to conduct
                                                                                            Heberprot‐P infiltration.

        14:00‐14:50         Patient No. 5. Ischemic Ulcer. Middle of wound healing.         To appreciate how an Ischemic ulcer which
                            Tissue in granulation.                                          is progressing well in term of granulation is
                                                                                            prepared for receiving Heberprot‐P
                                                                                            infiltration, after that they will see all
                                                                                            details about Heberprot‐P infiltration.

        15:00‐15:50                                                                 g
                            Patient No. 6. Ischemic Ulcer. Ulcer near to full healing.           pp
                                                                                            To appreciate how an Ischemic ulcer which
                                                                                            is progressing well in term of granulation
                                                                                            and is almost healed, is prepared for
                                                                                            receiving Heberprot‐P infiltration.
        16:00‐16:50         Interactive session between teachers and applicants.            To answer all type of questions based on
                                                                                            Heberprot‐P practical applications.
      CONFIRMED SPEAKERS
      CONFIRMED SPEAKERS
1.     Prof. Alberto Piaggesi. Head Diabetic Foot Section, Department of Endocrinology and Metabolism, University
       of Pisa, Pisa Italy. Italian representative of the International Working Group on the Diabetic Foot Consultative
       Section of IDF. Italy.
2.     Dr. Alfonso López. Editor Associated International Journal Gerontology Chronome Geriatrics Professor of
       Clinical Pharmacology M di l Di t Al ti Ph
       Cli i l Ph          l                                        México.
                                 Medical Director Alvartis Pharma. Mé i
3.     Dr. Fermin R. Martinez De Jesus<. President Mexican Association Diabetic Foot. Titular Member of the
       Mexican Chirurgic Society. Representative of Mexico in the International Working Group on the Diabetic
       Foot. San Elian Center for Salvage and Prevention of Diabetic Foot. Mexico.
4.     Dra Hermelinda C. Pedrosa. Director ‐ Department of Diabetic Foot ‐ Brazilian Diabetes
       Society. Representative of Brazil in the International Working Group on the Diabetic Foot ‐ Consultative
       Section of IDF. Brazil
5.     Dr. Jorge Berlanga. Technical Director of Heberprot‐P project. Senior Researcher, Chief of Inflamation
       Department. Center for Genetic Engineering and Biotechnology,Havana, Cuba.
6.     Dr. José Fernandez Montequin. 1st and 2nd degree specialist in Angiology and Vascular Surgery; Professor of
       the Medical University of Havana; Senior Researcher of the Cuban Institute of Angiology and Cardiovascular
       Surgery; Invited Medical Professor at Univ. John F. Kennedy , Argentina; and Technical University of Quito,
       Ecuador; Titular Member of the Cuban Society of Angiology and Vascular Surgery; Honorific member of the
                                                                                            cuador;
       Angiology and Cardiovascular Surgery Societies from Colombia, Honduras and Ecuador; Foreigner Member of
       the Phlebology Society from Argentina. Cuba.
7.     Dr. Josep Marinel.lo Roura. Dr. In Medicine and Surgery. Angiologist and vascular surgery. Jeff of the Vascular
       Surgery and Angiology Service of Mataró Hospital. CSdM Mataró, Barcelona‐Spain.
8.     Prof. Kelman Cohen. , M. D. Emeritus Professor of Surgery. Virginia Commonwealth University, Health
       Science Division Richmond, Virginia, United States
9.     Prof. Luigi Uccioli. Lecturer in Geriatric at the Medicine Faculty of Univ. of Rome “Tor Vergata” Coordinator or
       th I t S i t St d G              AMD‐SID. Italy.
       the Inter Society Study Group AMD SID It l
10.    Dr. Luis Herrera Martínez. Senior Researcher, Member of the Cuban Academic of Sciences, General Director
       of the Center for Genetic Engineering and Biotechnology, Havana, Cuba.
11.    Dr. Martin Braddock. Associated Director and Principal Senior Scientist within Discovery. AstraZeneca UK
       Limited. England.
12.    Prof. Dr. Maximilian Spraul. Diabetic Department, Mathias‐Spital, Rheine, Germany, Representative of
                y                              g       p
       Germany in the International Working Group on the Diabetic Foot ‐ Consultative Section of IDF. Germany.     y
13.    Dr. Pedro Lopez Saura. 2nd specialist in Clinic Biochemistry. Senior Researcher. Member of the Cuban
       Academic of Sciences. Director of Regulatory Issues and Clinical Affairs of the Center for Genetic Engineering
       and Biotechnology, Havana, Cuba.
14.    Dr. Peter A. Blume. D.P. M., F. A. C. F. A. S. Assistant Clinical Professor of Surgery Anesthesia and Orthopedics
       and Rehabilitation Yale School of Medicine. United States.
For further details, please  visit the Congress web site or contact us:


                • Manuel Raices Ph.D.
                Scientific Secretary BH2010
                Scientific Secretary BH2010

 • Center for Genetic Engineering and Biotechnology
        Ave 31/ 158 and 190, Cubanacan, Playa
        Ave 31/ 158 and 190 Cubanacan Playa
          P.O Box 6162, Havana 10600, CUBA
             • Phones: (53‐7) 271‐2397
                 Fax: (53‐7) 273‐6008
                 Fax: (53‐7) 273‐6008

          • Web site: http://bh2010.cigb.edu.cu
              E‐mail: bh2010@cigb.edu.cu  
              E mail: bh2010@cigb edu cu

								
To top